A compound tested on jet-lagged mice has cut recovery time nearly in half, wastewater pumped from transatlantic aircraft toilets caught a new coronavirus variant spreading a full month before conventional surveillance did, and the hospital accreditation body that underpins the medical tourism industry has just launched a new standard to sort genuine expertise from marketing. Travel is not just something life sciences studies from the outside. In 2026, the act of travelling itself is generating some of the field’s more useful data.
Airports, aircraft cabins and the disrupted sleep that comes with crossing time zones are not the first things that come to mind when people think about life sciences research. Yet travel puts the human body through conditions that are hard to replicate anywhere else, disrupted circadian rhythms, hundreds of strangers sharing recycled air for hours at a time, and a global mixing of pathogens that no laboratory could ethically simulate. Three developments this year show what happens when that reality is treated as an asset rather than an inconvenience.
A Drug Built to Fix the Body Clock
In February, a team of Japanese researchers led by Emeritus Professor Hajime Tei of Kanazawa University, working with colleagues at Osaka University, Toyohashi University of Technology and the Institute of Science Tokyo, published findings in the Proceedings of the National Academy of Sciences describing a compound called Mic-628 that can reliably push the body’s internal clock forward, something conventional treatments like melatonin or timed light exposure struggle to do consistently. The compound works by binding to CRY1, a protein that normally suppresses the activity of the clock gene Per1, forming a larger molecular complex that switches Per1 on regardless of when the drug is taken.
The practical test was a mouse model of jet lag, in which the animals’ light-dark cycle was abruptly advanced by six hours, mimicking a long eastbound flight. Mice given a single oral dose of Mic-628 adjusted to the new schedule in four days, compared with seven days for untreated animals. Because advancing the clock, as happens when travelling east or starting night shifts, is consistently harder on the body than delaying it, a drug that works in one direction reliably regardless of timing represents a genuinely different approach from existing options. The researchers describe the work as an early step: Mic-628 has not yet been tested in humans, and further studies will need to establish its safety before it could become what the team calls a “smart drug” for jet lag and shift work disorders. But the biological pathway it exploits, a dual E-box binding site that the drug complex activates directly, is now a clearly mapped target for future circadian medicine, discovered specifically because researchers wanted to solve a problem air travellers experience millions of times a year.
What Turns Up in an Aircraft Toilet
If jet lag research starts with the traveller’s body, a second strand of work this year starts with what travellers leave behind. Researchers from the UK Health Security Agency (UKHSA), the UK Department for Transport and US counterparts ran a six-month bilateral pilot testing whether wastewater collected from aircraft lavatory tanks could function as an early warning system for pathogens crossing borders, publishing their results in Scientific Reports. Samples were taken from a shared transatlantic route operated by two airlines: 308 samples from UK-origin flights tested at the US airport between March 2024 and January 2025, and 116 from US-origin flights tested at the UK airport between July 2024 and January 2025.
The results were striking. Of 424 total samples, 317 (74.8%) tested positive for at least one respiratory pathogen, among them SARS-CoV-2, influenza A, influenza B and RSV, while 303 (71.5%) tested positive for at least one enteric pathogen, including norovirus and adenovirus. The most telling finding concerned a SARS-CoV-2 variant called XEC. The samples showed XEC appearing on UK-origin flights from 17 September 2024, a full four weeks before it turned up on US-origin flights, on 14 October. That gap tracked real-world events closely: although the first clinical case of XEC in the US was recorded back in July 2024, wider community transmission did not take hold until mid-October, almost exactly when the aircraft wastewater signal picked it up. The authors were careful to flag the pilot’s limits, it covered only two airports and two airlines, used different laboratory methods on each side of the Atlantic, and cannot estimate how many passengers on a given flight were actually infected, but concluded that expanding the network to more airports and harmonising testing methods could meaningfully improve early warning capability for the next pandemic threat.
Sorting Genuine Expertise From a Marketing Claim
The third development is less about biology and more about the industry that has grown up around people travelling specifically to receive medical care. Estimates of the global medical tourism market vary considerably depending on methodology, but industry analyses generally put the figure somewhere in the tens of billions of dollars a year, with patient volumes commonly estimated at somewhere between 14 and 21 million people travelling internationally for treatment annually, drawn by lower costs, shorter waiting lists or access to procedures unavailable at home. Even at the conservative end of those estimates, that scale has long outpaced the ability of patients to judge which overseas providers are genuinely excellent and which are simply well marketed.
In June, Joint Commission International (JCI), the body whose hospital accreditation has functioned as the industry’s main quality benchmark for decades, launched a new Center of Excellence certification aimed at closing that gap. Unlike JCI’s broader hospital accreditation, the new certification assesses individual clinical service lines rather than an entire institution, and does not require a hospital to already hold full JCI accreditation before applying. At launch it covers five specialties: pediatrics, oncology, trauma, orthopedics and maternal-perinatal care, with JCI stating it intends to expand into further specialties as the programme matures. Jonathan Perlin, JCI’s president and chief executive, was blunt about why the certification exists: “The term ‘Center of Excellence’ is widely used in healthcare, but often without a consistent or objective basis for how it is defined or evaluated. Any hospital can simply call itself a Center of Excellence, and many do, but the new JCI Center of Excellence Certification fills that gap.” For a sector where a patient’s choice of provider is often made from another country, based on a website and a handful of reviews, a credential that specifically distinguishes service-line expertise from general hospital accreditation is a meaningful addition to the information a prospective medical traveller can actually verify.
Movement as Method
None of these three developments would exist without people moving across time zones, borders and oceans. A jet lag drug is only worth discovering because millions of people cross time zones and suffer for it. A pathogen surveillance network only works because a shared transatlantic route carries the same population of travellers, and their waste, in a predictable, sample-able pattern day after day. And a new accreditation standard only matters because patients have been travelling in growing numbers to seek care that is not available, affordable or timely enough at home. Travel is usually framed as a life sciences problem, jet lag to manage, infection risk to mitigate, care quality to verify from a distance. What 2026 has shown is that it can just as easily be framed as a life sciences resource: a naturally occurring, globally distributed experiment that researchers are only beginning to take full advantage of.
Sources include the Proceedings of the National Academy of Sciences, Kanazawa University, Scientific Reports, News-Medical, Joint Commission International and Becker’s Hospital Review.
